Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
研究概览
地位
地位
干预/治疗
干预/治疗
研究类型
研究类型
注册 (预期的)
注册
阶段
阶段
- 不适用
联系人和位置
学习联系方式
学习联系方式
- 姓名:Sun Tao, Doctor
- 电话号码:13940404526
- 邮箱:lnzlrxnsy@163.com
学习地点
-
-
Liaoning
-
Shenyang、Liaoning、中国、110042
- 招聘中
- Liangning Tumor Hospital &Institute
-
接触:
- Sun Tao, Doctor
- 电话号码:13940404526
- 邮箱:lnzlrxnsy@163.com
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- women aged ≥ 18 years, histologically or cytologically confirmed HR positive (ER expression ≥ 10%, PR positive or negative), HER2 negative breast cancer patients;
- before enrollment for unresectable locally advanced or metastatic breast cancer, and at least one measurable lesion or no measurable lesion and bone metastasis alone patients;
For locally advanced or metastatic breast cancer, no previous endocrine therapy or first-line endocrine therapy, and no previous use of CDK4/6 inhibitors. Specifically, it includes the following conditions:
Cohort 1: (neo) recurrence > 12 months after the end of adjuvant endocrine therapy, and without any rescue therapy · newly diagnosed advanced breast cancer without any rescue therapy Cohort 2: (neo) recurrence during or ≤ 12 months after the completion of adjuvant endocrine therapy, and without any rescue therapy · recurrence > 12 months after the completion of adjuvant endocrine therapy, and progression by first-line endocrine therapy · newly diagnosed advanced breast cancer and progression by first-line endocrine rescue therapy
- Cohort 1 without previous chemotherapy for advanced breast cancer; Cohort 2 with ≤ 1 previous chemotherapy for advanced breast cancer;
- no brain metastasis or asymptomatic brain metastasis;
- ECOG score 0-1;
- Absolute neutrophil count ≥ 1.5 × 109/L, platelet ≥ 100 × 109/L, hemoglobin ≥ 90 g/L;
- Expected survival time ≥ 3 months;
- Voluntarily participate in this clinical trial, sign the written informed consent;
Exclusion Criteria:
- no measurable lesions (except bone metastases alone), such as pleural or pericardial exudates, ascites, etc.
- Patients who have undergone major surgical procedures or significant trauma before enrollment, or are expected to undergo major surgical treatment
- Patients who have previously been treated with CDK4/6 inhibitors, fulvestrant or HDAC inhibitors (including romidepsin, vorinostat, berlistat, parabrestat), but have received 1 cycle (≤ 2 times, on d1, d15, respectively) of fulvestrant within 28 days (before enrollment) are allowed
- Known history of allergy to the drug components of this protocol
- Meningeal metastasis before enrollment
- Uncontrollable serosal effusion
- Active infection [an active bacterial, viral, fungal, mycobacterial, parasitic or other infection (excluding fungal infections of the nail bed) within 4 months prior to Screening or any major infectious event requiring intravenous antibiotics, or targeted antiviral therapy, or hospitalization], or persistent fever within 14 days prior to Screening
- a history of immunodeficiency, including HIV test positive, or suffering from other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
- according to the investigator's judgment, there are serious hazards to the patient's safety, or affect the patient to complete the study of concomitant diseases (such as: severe hypertension, diabetes, thyroid disease, active infection, etc.);
- History of definite neurological or psychiatric disorders, including epilepsy or dementia
- Subjects who, in the opinion of the investigator, are not suitable for the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:西达本胺+氟维司群
|
chidamide 30mg orally,Biw
Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
总缓解率 (ORR)
大体时间:最长约 26 个月
|
根据 RECIST 1.1,总体缓解率 (ORR) 定义为具有完全缓解 (CR) 或部分缓解 (PR) 的最佳总体缓解的患者比例。
|
最长约 26 个月
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
总生存期(OS)
大体时间:最长约 58 个月
|
从随机化日期到任何原因死亡日期的时间。
|
最长约 58 个月
|
|
Progression Free Survival (PFS)
大体时间:Up to approximately 26 months
|
PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause.
|
Up to approximately 26 months
|
|
Clinical Benefit Rate (CBR)
大体时间:Up to approximately 26 months
|
Clinical benefit rate (CBR), defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) lasting 24 weeks or longer as defined in RECIST 1.1.
|
Up to approximately 26 months
|
|
Duration of Response (DOR)
大体时间:Up to approximately 26 months
|
Time from the first documented response (CR or PR) to the first documented progression or death due to underlying cancer as defined in RECIST 1.1.
|
Up to approximately 26 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (预期的)
初级完成
研究完成 (预期的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- CSIIT-C18
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.